As part of its development of new diagnostic and prognostic solutions for liver cancer, Ophiomics conducts research using data from patients, and conducts retrospective and prospective clinical studies. These all raise multiple ethics issues. We are happy to announce that Prof. Ana Sofia Carvalho is joining our Advisory Board as our Ethics Mentor. Prof. Carvalho
Ophiomics wins EIC accelerator funding in its pilot scheme. This hybrid funding scheme that includes a grant together with investment from the European Investment Bank, will permit Ophiomics to take HepatoPredcit to market and make a difference in selecting the right patients cancer for liver transplantation.
Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page. This grant will permit Ophiomics to build a business case for HepatoPredict.